Duke spinout has new method to get T cell engagers across the blood-brain barrier

Adaptin emerged from stealth in September with tech licensed from Duke University that can transport bispecific antibodies to tissues of interest, including the brain, and IND clearance from FDA to test its lead candidate in glioblastoma.

Naive T cells can't cross the blood-brain barrier (BBB), but if the brain sends out signals that something is wrong, the T cells can express receptors on their cell surfaces that facilitate entry...